These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9783412)

  • 21. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholera vaccine inactivated oral.
    Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
    [No Abstract]   [Full Text] [Related]  

  • 23. Cholera vaccines: fighting an ancient scourge.
    Mekalanos JJ; Sadoff JC
    Science; 1994 Sep; 265(5177):1387-9. PubMed ID: 8073279
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of antibody responses and protective immunity in cholera vaccinated subjects.
    Chaicumpa W; Pacharaprakiti C; Plueksawan W; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Mar; 11(1):58-66. PubMed ID: 7403955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assay of cholera vaccine potency.
    Mumford JA; Ford AW; Richer PR
    J Biol Stand; 1977; 5(4):351-67. PubMed ID: 925045
    [No Abstract]   [Full Text] [Related]  

  • 26. Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasons.
    Gupta SS; Bharati K; Sur D; Khera A; Ganguly NK; Nair GB
    Indian J Med Res; 2016 May; 143(5):545-51. PubMed ID: 27487997
    [No Abstract]   [Full Text] [Related]  

  • 27. Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains.
    García Imia L; Oliva Hernández R; Cedré Marrero B; Valmaseda Pérez T; García Sánchez H; Talavera Coronel A; Pérez Quiñoy JL; Sierra González G
    Lab Anim Sci; 1998 Oct; 48(5):538-41. PubMed ID: 10090073
    [No Abstract]   [Full Text] [Related]  

  • 28. Recent progress in cholera vaccination.
    Pierre PG; Lucas G; Van Damme M; Vaerman JP
    Acta Gastroenterol Belg; 1992; 55(5-6):430-6. PubMed ID: 1288041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholera vaccines.
    Kabir S
    Lancet Infect Dis; 2007 Mar; 7(3):176-8; author reply 178. PubMed ID: 17317594
    [No Abstract]   [Full Text] [Related]  

  • 32. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
    Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
    Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An oral B subunit: whole cell vaccine against cholera.
    Holmgren J; Svennerholm AM; Jertborn M; Clemens J; Sack DA; Salenstedt R; Wigzell H
    Vaccine; 1992; 10(13):911-4. PubMed ID: 1471411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera.
    Bondre VP; Sinha VB; Srivastava BS
    FEMS Immunol Med Microbiol; 1997 Dec; 19(4):323-9. PubMed ID: 9537758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular design of cholera vaccines.
    Manning PA
    Vaccine; 1992; 10(14):1015-21. PubMed ID: 1361701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Selection of attenuated Vibrio cholerae strains to obtain oral attenuated candidate vaccines against cholera].
    María García H; Año G; Cedré B; Valmaseda T; Maestre JL; Díaz M; Mirabal M; Talavera A; García L
    Rev Cubana Med Trop; 2005; 57(2):92-104. PubMed ID: 17966578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The outer membranes of Vibrio cholerae as a potential component in a chemical vaccine].
    Markov EIu; Urbanovich LIa; Golubinskiĭ EP; Chernov AB; Karetnikova ES; Ivanova TA; Pakulev NA
    Zh Mikrobiol Epidemiol Immunobiol; 1995; Suppl 2():86-9. PubMed ID: 7771156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cholera update and vaccination problems].
    Fournier JM; Villeneuve S
    Med Trop (Mars); 1998; 58(2 Suppl):32-5. PubMed ID: 9812307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
    Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
    Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.